Moraiya facility is the company’s largest formulations manufacturing unit.
Buy / Sell Zydus Life share
Recommended ArticlesView All
Decoding multi-year health insurance policy — What is it and what are key benefits?
IST3 Min(s) Read
View | Pakistan Election: Will Imran Khan's changed tack from long march to resignations to snap poll work?
IST5 Min(s) Read
View | G20 Presidency: India can shape global Web3 narrative
IST6 Min(s) Read
Zydus Lifesciences Ltd. has received an establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing unit at Moraiya, near Ahmedabad in Gujarat.
Moraiya facility is the company’s largest formulations manufacturing unit and it was issued a Warning Letter in November 2019 by USFDA. An approval with Voluntary Action Indicated (VAI) means objectionable conditions or practices were found at the manufacturing unit but USFDA does not recommend any administrative or regulatory action.
The EIR nod from USFDA for the Moraiya plant could pave the way for more approvals from the US drug regulator for a higher number of transdermal products and some limited competition products from Zydus Lifesciences in the coming months.
Zydus Lifesciences, the Ahmedabad headquartered company, develops, manufactures, and markets a broad range of healthcare therapies. The Zydus group has research facilities across Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. It also has manufacturing and research units in the US and Brazil.